Orphazyme ApS, founded in 2009, develops paradigm-changing medicine for the treatment of a family of genetic disorders called lysosomal storage diseases. This family consists of more than 45 diseases, most of which are currently untreatable and often fatal. Lysosomal storage diseases affect mostly children who often die at a young and unpredictable age, many within a few years of birth. Other patients live longer, but ultimately die following years of suffering from defects in various organs such as the kidneys, liver, heart and CNS.

Orphazyme extends its seed financing by raising €3 million (22 mDDK) from new investor Sunstone Capital as well as existing shareholder Novo A/S. In conjunction with the investment, Bo Jesper Hansen, Chairman of the board at public company Swedish Orphan Biovitrum, and Sten Verland, Partner Sunstone Capital, will join the board of directors. They add significant expertise and experience with the development and commercialization of orphan drugs.

"We are happy to announce this seed round extension, and delighted to have Sunstone Capital join as an investor. Orphazyme has progressed the last 12 months and we are now starting to prepare our lead project for clinical development. By the addition of Bo Jesper Hansen and Sten Verland to the board, we gain significant resources and experience, which will allow us to develop at full speed our novel class of therapeutics for lysosomal storage diseases", says Anders Hinsby, CEO of Orphazyme.

Sten Verland, Sunstone Capital, comments: "We are happy to join Novo as co-investors in Orphazyme. Their innovative approach promises to deliver new treatments for a number of lysosomal storage diseases. The orphan drug indication area fits well into our investment strategy, and we are looking forward to follow the progress of the company%u2019s lead project toward clinical testing".

For more information about Orphazyme:

Anders Hinsby, CEO: e-mail: amh@orphazyme.com, tel: 0045 7070 2980

For more information about Novo A/S and Novo Seeds:

Henrijette Richter, Investment Director: e-mail: heri@novo.dk, tel: 0045 3527 6500

For more information about Sunstone Capital:

Sten Verland, Partner: verland@sunstonecapital.com, tel: 0045 2422 1969

About Orphazyme

Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.

About Sunstone Capital

Sunstone Capital is a Nordic-based early stage venture capital investor founded by an international team with more than 200 years of combined entrepreneurial, operational and financial experience. With approximately €500 million in funds under management, Sunstone focuses on developing and expanding early-stage Life Science and Technology companies with strong potential to achieve global success in their markets.

About Novo Seeds

Novo Seeds is a life science supporting program launched by the Novo Nordisk Foundation and Novo A/S. Novo Seeds has two components, a pre-seed funding capacity and a seed financing fund. Both aim at identifying and developing the unexplored commercial potential present in academic and early stage applied research projects at universities and biotech companies within life science in Scandinavia.